NO20025089L - Farmasöytiske preparater - Google Patents
Farmasöytiske preparaterInfo
- Publication number
- NO20025089L NO20025089L NO20025089A NO20025089A NO20025089L NO 20025089 L NO20025089 L NO 20025089L NO 20025089 A NO20025089 A NO 20025089A NO 20025089 A NO20025089 A NO 20025089A NO 20025089 L NO20025089 L NO 20025089L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparations
- ascomycin
- derivative
- pharmaceutical composition
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9514397.0A GB9514397D0 (en) | 1995-07-14 | 1995-07-14 | Organic compounds |
GBGB9515025.6A GB9515025D0 (en) | 1995-07-21 | 1995-07-21 | Organic compounds |
PCT/EP1996/003066 WO1997003654A2 (en) | 1995-07-14 | 1996-07-12 | Pharmaceutical compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20025089L true NO20025089L (no) | 1998-01-18 |
NO20025089D0 NO20025089D0 (no) | 2002-10-23 |
NO317702B1 NO317702B1 (no) | 2004-12-06 |
Family
ID=26307397
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19980081A NO314924B1 (no) | 1995-07-14 | 1998-01-08 | Farmasöytisk preparat omfattende rapamycin eller et derivat derav samt fremgangsmåte for fremstilling derav |
NO20025089A NO317702B1 (no) | 1995-07-14 | 2002-10-23 | Farmasoytiske preparater |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19980081A NO314924B1 (no) | 1995-07-14 | 1998-01-08 | Farmasöytisk preparat omfattende rapamycin eller et derivat derav samt fremgangsmåte for fremstilling derav |
Country Status (31)
Country | Link |
---|---|
US (5) | US6004973A (no) |
EP (2) | EP1281400B1 (no) |
JP (4) | JPH11509223A (no) |
KR (1) | KR100352943B1 (no) |
CN (1) | CN1080120C (no) |
AT (2) | ATE258429T1 (no) |
AU (1) | AU706174B2 (no) |
BE (1) | BE1009856A5 (no) |
BR (1) | BR9609537A (no) |
CA (2) | CA2426956C (no) |
CL (1) | CL2003002715A1 (no) |
CY (2) | CY2603B2 (no) |
CZ (1) | CZ291305B6 (no) |
DE (2) | DE69635499T2 (no) |
DK (2) | DK1281400T3 (no) |
ES (2) | ES2250566T3 (no) |
FR (1) | FR2736550B1 (no) |
HK (1) | HK1016081A1 (no) |
HU (1) | HU226774B1 (no) |
IL (2) | IL122905A (no) |
IT (1) | IT1284871B1 (no) |
NO (2) | NO314924B1 (no) |
NZ (1) | NZ313633A (no) |
PL (1) | PL191933B1 (no) |
PT (1) | PT839028E (no) |
RU (1) | RU2159107C2 (no) |
SI (2) | SI0839028T1 (no) |
SK (2) | SK283571B6 (no) |
TR (1) | TR199800045T1 (no) |
UY (1) | UY25896A1 (no) |
WO (1) | WO1997003654A2 (no) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
TW570814B (en) * | 1998-03-26 | 2004-01-11 | Fujisawa Pharmaceutical Co | Sustained-release pharmaceutical composition |
JP3718341B2 (ja) | 1998-05-12 | 2005-11-24 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースとその製造方法 |
US20060240070A1 (en) * | 1998-09-24 | 2006-10-26 | Cromack Keith R | Delivery of highly lipophilic agents via medical devices |
GB9826882D0 (en) * | 1998-12-07 | 1999-01-27 | Novartis Ag | Organic compounds |
AU2003200370B2 (en) * | 1998-12-07 | 2005-10-27 | Novartis Ag | Stabilization of macrolides |
EP1181034B1 (en) | 1999-05-10 | 2010-07-21 | Paolo Brenner | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
EP1054019A1 (en) | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
JP3552160B2 (ja) | 2000-01-14 | 2004-08-11 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース粒子の形成方法 |
IL134701A0 (en) | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
EP1389108A2 (en) * | 2001-05-09 | 2004-02-18 | Novartis AG | Methods for selective immunomodulation using pimecrolimus |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
AU2006218279B2 (en) * | 2001-09-28 | 2009-12-10 | Novartis Ag | Pharmaceutical compositions comprising colloidal silicon dioxide |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1469832B2 (en) | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
DK1478648T3 (da) | 2002-02-01 | 2014-07-28 | Ariad Pharma Inc | Phosphorholdige forbindelser og anvendelser deraf |
EP1469829B1 (en) * | 2002-02-01 | 2016-01-27 | Bend Research, Inc | Immediate release dosage forms containing solid drug dispersions |
JP3956114B2 (ja) * | 2002-06-28 | 2007-08-08 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 表示制御方法、これを用いたプログラム、情報処理装置及び光学式文字読み取り装置 |
EP1585738A2 (en) * | 2002-11-15 | 2005-10-19 | Novartis AG | Drug delivery system |
AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
WO2005004848A1 (en) * | 2003-07-09 | 2005-01-20 | Chong Kun Dang Pharmaceutical Corp. | The solid dispersion of tacrolimus |
CA2532931A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
UA84881C2 (ru) * | 2003-09-03 | 2008-12-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его |
CN1882338A (zh) | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
PL1701698T3 (pl) * | 2004-01-08 | 2008-03-31 | Wyeth Corp | Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779 |
US7655442B2 (en) | 2004-01-29 | 2010-02-02 | Eisai R&D Management Co., Ltd. | Method for stabilizing macrolide compounds |
CN101098678A (zh) * | 2004-04-23 | 2008-01-02 | 锡德克斯公司 | 含有磺基烷基醚环糊精的dpi制剂 |
ATE483716T1 (de) | 2004-08-27 | 2010-10-15 | Cordis Corp | Lösungsmittelfreies amorphes rapamycin |
CN101076319A (zh) * | 2004-09-29 | 2007-11-21 | 科迪斯公司 | 稳定的非晶形雷帕霉素样化合物的药物剂型 |
US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP4974903B2 (ja) | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
BRPI0608573A2 (pt) * | 2005-03-08 | 2017-07-25 | Lifecycle Pharma As | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
ATE533520T1 (de) * | 2005-03-23 | 2011-12-15 | Abbott Lab | Abgabe von stark lipophilen mitteln durch medizinprodukte |
US20060240108A1 (en) * | 2005-04-26 | 2006-10-26 | Bernard Bobby L | Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability |
DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
AU2006315512B2 (en) | 2005-11-14 | 2012-11-01 | Ariad Pharmaceuticals, Inc. | Administration of an mTOR inhibitor to treat patients with cancer |
US7700614B2 (en) | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
BRPI0707612B8 (pt) | 2006-02-09 | 2021-05-25 | Macusight Inc | vaso lacrado e formulações líquidas contidas no mesmo |
CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
ES2405364T3 (es) | 2006-12-29 | 2013-05-30 | Abbott Laboratories | Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera |
ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
WO2008082984A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
EP1952807A1 (en) * | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
BRPI0909187A2 (pt) | 2008-03-20 | 2015-08-04 | Virun Inc | Emulsões incluindo tocoferol de derivados de peg |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
EP2365802B1 (en) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
FR2943539B1 (fr) | 2009-03-31 | 2011-07-22 | Ethypharm Sa | Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus. |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2011079127A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
WO2011119228A1 (en) | 2010-03-23 | 2011-09-29 | Virun, Inc. | Nanoemulsion including sucrose fatty acid ester |
KR101620661B1 (ko) | 2010-04-27 | 2016-05-12 | 로슈 글리카트 아게 | 어푸코실화된 CD20 항체와 mTOR 억제제의 복합 요법 |
IT1400977B1 (it) * | 2010-07-01 | 2013-07-05 | Euticals Spa | Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
WO2012058392A1 (en) | 2010-10-29 | 2012-05-03 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
CN105664164B (zh) | 2010-11-23 | 2020-05-05 | 艾伯维巴哈马有限公司 | 使用选择性的bcl-2抑制剂的治疗方法 |
WO2012092421A2 (en) * | 2010-12-30 | 2012-07-05 | Surmodics, Inc. | Composition for intravascular delivery of therapeutic composition |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
US20120303115A1 (en) * | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
US8809562B2 (en) | 2011-06-06 | 2014-08-19 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
WO2013022201A1 (en) * | 2011-08-11 | 2013-02-14 | Dong-A Pharm. Co., Ltd. | Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
BR112014007902A2 (pt) | 2011-10-06 | 2017-04-18 | Novartis Ag | composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina |
EP2594260A1 (en) * | 2011-11-18 | 2013-05-22 | LEK Pharmaceuticals d.d. | Solid preparations comprising sirolimus with desired bioavailability and method for its preparation |
US8912215B2 (en) * | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
KR200477251Y1 (ko) * | 2011-12-30 | 2015-05-22 | 엘에스산전 주식회사 | 배선용 차단기의 주 접점 위치 표시 기구 |
CN103585122B (zh) * | 2012-08-17 | 2017-12-05 | 山东新时代药业有限公司 | 一种含依维莫司的片剂及其制备方法 |
EP2906214A1 (en) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
US9610385B2 (en) | 2013-03-07 | 2017-04-04 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device comprising a rapamycin derivative |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事(everolimus)之醫藥組合物 |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
AU2014332080B2 (en) | 2013-10-08 | 2020-02-27 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
CN105899232A (zh) | 2013-11-13 | 2016-08-24 | 诺华股份有限公司 | 用于增强免疫应答的mTOR抑制剂 |
CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
SG11201604815RA (en) | 2013-12-19 | 2016-07-28 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
KR20160120739A (ko) | 2014-02-11 | 2016-10-18 | 램 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
FI3125875T3 (fi) | 2014-04-04 | 2023-08-24 | Ai Therapeutics Inc | Inhaloitava rapamysiiniformulaatio ikäsidonnaisten tilojen hoitoon |
LT3888674T (lt) | 2014-04-07 | 2024-07-25 | Novartis Ag | Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių |
CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
BR112016028211A2 (pt) | 2014-06-02 | 2017-10-24 | Childrens Medical Center | métodos e composições para imunomodulação |
KR102594343B1 (ko) | 2014-07-21 | 2023-10-26 | 노파르티스 아게 | Cd33 키메라 항원 수용체를 사용한 암의 치료 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
EA201790624A1 (ru) | 2014-09-17 | 2017-08-31 | Новартис Аг | Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии |
EP3209330B1 (en) | 2014-10-07 | 2022-02-23 | AI Therapeutics, Inc. | An inhalable sirolimus formulation for the treatment of pulmonary hypertension |
IL279420B1 (en) | 2014-10-08 | 2024-05-01 | Novartis Ag | Biomarkers for predicting drug reactivity to chimeric antigen receptor therapy and their use |
MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
WO2017038612A1 (ja) * | 2015-08-28 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
WO2017038925A1 (ja) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
WO2017204215A1 (ja) | 2016-05-27 | 2017-11-30 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
JP6857663B2 (ja) * | 2016-10-04 | 2021-04-14 | 日本化薬株式会社 | ラパマイシン誘導体を含有する固体分散体の製造方法 |
AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
CN107080738A (zh) * | 2017-04-26 | 2017-08-22 | 四川制药制剂有限公司 | 乙酰螺旋霉素片的制备方法 |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3848065B1 (en) | 2017-05-15 | 2023-07-26 | C. R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US11541152B2 (en) | 2018-11-14 | 2023-01-03 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
US20220176084A1 (en) | 2019-04-08 | 2022-06-09 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3741367A1 (en) | 2019-05-21 | 2020-11-25 | Premark Pharma GmbH | Treatment of ocular disease |
EP3991750A4 (en) * | 2019-06-26 | 2022-08-03 | Ricoh Company, Ltd. | PHARMACEUTICAL COMPOSITION |
US20220401421A1 (en) * | 2019-12-19 | 2022-12-22 | Triviumvet Dac | Veterinary formulations comprising rapamycin and methods of using the same for treating animal disease |
WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3852421A (en) | 1970-03-23 | 1974-12-03 | Shinetsu Chemical Co | Excipient and shaped medicaments prepared therewith |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
US4248856A (en) | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
JPS5620513A (en) | 1979-07-31 | 1981-02-26 | Eisai Co Ltd | Sugar-coated tablet containing fat-soluble drug |
US4309405A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
US4415547A (en) | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
US4650666A (en) | 1983-11-30 | 1987-03-17 | Dainippon Pharmaceutical Co., Ltd. | Pullulan and sugar coated pharmaceutical composition |
US4753801A (en) | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US4659336A (en) | 1986-03-28 | 1987-04-21 | Texaco Inc. | Motor fuel composition |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
DE3823702A1 (de) | 1988-07-13 | 1990-01-25 | Bayer Ag | Verfahren zur herstellung von acryloylgruppen enthaltenden polyestern und ihre verwendung als lackbindemittel |
GB2222683B (en) | 1988-08-17 | 1992-04-15 | Hydramotion Ltd | Device for moisture measurement of particulate material |
PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
DE10299040I2 (de) * | 1989-11-09 | 2006-08-24 | Novartis Ag | Heteroatome enthaltende tricyclische Verbindungen |
US5352671A (en) * | 1989-11-09 | 1994-10-04 | Sandoz Ltd. | Heteroatoms-containing tricyclic compounds |
JPH03240726A (ja) * | 1990-02-15 | 1991-10-28 | Fujisawa Pharmaceut Co Ltd | 化学療法効果増強剤 |
US5260301A (en) | 1990-03-01 | 1993-11-09 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical solution containing FK-506 |
JP2542122B2 (ja) | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | 球状核、球形顆粒およびその製造方法 |
JPH05507090A (ja) | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | 直接噴霧乾燥された薬剤/脂質粉末組成物 |
US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
JP2675194B2 (ja) | 1990-08-10 | 1997-11-12 | スミスクライン・ビーチャム・コーポレイション | 免疫抑制組成物 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
IL101353A0 (en) | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
KR0182801B1 (ko) * | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
DE69231644T2 (de) * | 1991-04-26 | 2001-05-23 | Fujisawa Pharmaceutical Co., Ltd. | Verwendung von makrolid-verbindungen gegen augenerkrankungen |
ATE135583T1 (de) | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
IL102414A (en) * | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
US5457111A (en) | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5817333A (en) | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
SG49652A1 (en) | 1992-03-30 | 1998-06-15 | American Home Prod | Rapamycin formulation for iv injection |
KR100284210B1 (ko) | 1992-04-28 | 2001-03-02 | 이건 이. 버그 | 과증식성 혈관 질환 치료용 배합 제제 |
US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5315246A (en) | 1992-08-19 | 1994-05-24 | Eastman Kodak Company | Rotating source for generating a magnetic field for use with a currency detector |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5457194A (en) | 1993-03-17 | 1995-10-10 | Abbott Laboratories | Substituted aliphatic amine-containing macrocyclic immunomodulators |
GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
US5352783A (en) | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
DE4322826A1 (de) | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
DE4329503A1 (de) | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5616588A (en) | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
GB9326284D0 (en) | 1993-12-23 | 1994-02-23 | Erba Carlo Spa | Pyrrolydenemethyl-derivatives and process for their preparation |
WO1995033490A1 (en) | 1994-06-02 | 1995-12-14 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
FR2722984B1 (fr) * | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
SE9403846D0 (sv) * | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5759577A (en) | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
EP0808154B1 (en) | 1995-02-06 | 2000-12-20 | Elan Pharma International Limited | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
US5616595A (en) * | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Process for recovering water insoluble compounds from a fermentation broth |
ES2181877T3 (es) * | 1995-06-07 | 2003-03-01 | Conoco Inc | Hilatura de fibras de carbono a partir de breas solvatadas. |
DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
US5766623A (en) | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
DE19635999A1 (de) | 1996-09-05 | 1998-03-12 | Dystar Textilfarben Gmbh & Co | Farbstoffmischungen von faserreaktiven Azofarbstoffen und ihre Verwendung zum Färben von hydroxy- und/oder carbonamidgruppenhaltigem Fasermaterial |
US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
-
1996
- 1996-07-11 BE BE9600631A patent/BE1009856A5/fr active
- 1996-07-11 FR FR9608705A patent/FR2736550B1/fr not_active Expired - Lifetime
- 1996-07-12 PT PT96925741T patent/PT839028E/pt unknown
- 1996-07-12 DK DK02023033T patent/DK1281400T3/da active
- 1996-07-12 CA CA002426956A patent/CA2426956C/en not_active Expired - Fee Related
- 1996-07-12 EP EP02023033A patent/EP1281400B1/en not_active Expired - Lifetime
- 1996-07-12 HU HU9900391A patent/HU226774B1/hu unknown
- 1996-07-12 ES ES02023033T patent/ES2250566T3/es not_active Expired - Lifetime
- 1996-07-12 IL IL12290596A patent/IL122905A/xx active Protection Beyond IP Right Term
- 1996-07-12 AT AT96925741T patent/ATE258429T1/de active
- 1996-07-12 NZ NZ313633A patent/NZ313633A/xx not_active IP Right Cessation
- 1996-07-12 JP JP9506264A patent/JPH11509223A/ja not_active Withdrawn
- 1996-07-12 EP EP96925741A patent/EP0839028B1/en not_active Expired - Lifetime
- 1996-07-12 KR KR10-1998-0700244A patent/KR100352943B1/ko not_active IP Right Cessation
- 1996-07-12 CZ CZ199891A patent/CZ291305B6/cs not_active IP Right Cessation
- 1996-07-12 AT AT02023033T patent/ATE310519T1/de not_active IP Right Cessation
- 1996-07-12 DE DE69635499T patent/DE69635499T2/de not_active Expired - Fee Related
- 1996-07-12 CN CN96196788A patent/CN1080120C/zh not_active Expired - Lifetime
- 1996-07-12 IT IT96RM000501A patent/IT1284871B1/it active IP Right Grant
- 1996-07-12 SK SK44-98A patent/SK283571B6/sk not_active IP Right Cessation
- 1996-07-12 SI SI9630671T patent/SI0839028T1/xx unknown
- 1996-07-12 ES ES96925741T patent/ES2215195T3/es not_active Expired - Lifetime
- 1996-07-12 RU RU98102855/14A patent/RU2159107C2/ru active Protection Beyond IP Right Term
- 1996-07-12 AU AU66152/96A patent/AU706174B2/en not_active Expired
- 1996-07-12 US US08/981,952 patent/US6004973A/en not_active Expired - Lifetime
- 1996-07-12 CA CA002225960A patent/CA2225960C/en not_active Expired - Lifetime
- 1996-07-12 SK SK186-2002A patent/SK283572B6/sk not_active IP Right Cessation
- 1996-07-12 DE DE69631422T patent/DE69631422T2/de not_active Expired - Lifetime
- 1996-07-12 WO PCT/EP1996/003066 patent/WO1997003654A2/en active IP Right Grant
- 1996-07-12 SI SI9630730T patent/SI1281400T1/sl unknown
- 1996-07-12 IL IL144684A patent/IL144684A/en not_active IP Right Cessation
- 1996-07-12 DK DK96925741T patent/DK0839028T3/da active
- 1996-07-12 PL PL324502A patent/PL191933B1/pl unknown
- 1996-07-12 BR BR9609537A patent/BR9609537A/pt not_active Application Discontinuation
- 1996-07-12 TR TR1998/00045T patent/TR199800045T1/xx unknown
-
1998
- 1998-01-08 NO NO19980081A patent/NO314924B1/no not_active IP Right Cessation
-
1999
- 1999-03-29 HK HK99101280A patent/HK1016081A1/xx not_active IP Right Cessation
- 1999-08-13 US US09/374,899 patent/US6197781B1/en not_active Expired - Lifetime
-
2000
- 2000-01-13 UY UY25896A patent/UY25896A1/es not_active Application Discontinuation
-
2002
- 2002-07-12 US US10/194,826 patent/US6599535B2/en not_active Expired - Fee Related
- 2002-10-23 NO NO20025089A patent/NO317702B1/no not_active IP Right Cessation
-
2003
- 2003-06-04 US US10/454,017 patent/US6956043B2/en not_active Expired - Fee Related
- 2003-07-11 JP JP2003273402A patent/JP2004002457A/ja not_active Withdrawn
- 2003-12-22 CL CL200302715A patent/CL2003002715A1/es unknown
-
2005
- 2005-07-26 CY CY0500043A patent/CY2603B2/xx unknown
- 2005-10-21 US US11/255,359 patent/US20060115533A1/en not_active Abandoned
-
2007
- 2007-02-09 CY CY0700003A patent/CY2571B1/xx unknown
-
2008
- 2008-02-29 JP JP2008049742A patent/JP5522901B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-22 JP JP2011281577A patent/JP2012082217A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20025089D0 (no) | Farmasöytiske preparater | |
AU638346B2 (en) | Carbostyril derivatives and pharmaceutical composition containing the same | |
HRP980163B1 (en) | Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates | |
TR199701567T1 (xx) | Rapamisin t�revleri. | |
AU7076887A (en) | Nasal administration of drugs | |
ATE243516T1 (de) | Amoxicillin und clavulanat enthaltende arzneizubereitungen | |
MY124487A (en) | Dolastatin derivatives, their preparation and use | |
DZ1717A1 (fr) | Nouvelles compositions pharmaceutiques à base de dérivés de nomegestrol et leur procédés d'obtention. | |
AU3635693A (en) | 1,4-dialkylpiperazine derivatives, method for obtaining them and pharmaceutical compositions containing them | |
AU1256792A (en) | Indole derivatives and pharmaceutical compositions containing them | |
FR2767526B1 (fr) | Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant | |
NO951350D0 (no) | Farmasöytiske preparater inneholdende 3-substituerte 2-oksindol-1-karboksamider | |
BR9106372A (pt) | Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico | |
DK0457215T3 (da) | 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf | |
KR900700471A (ko) | 신규의 2,3-티오모르폴린디온-2-옥심유도체, 이들을 함유하는 약제학적 조성물 및 제법 | |
DE69434010D1 (de) | C7-Taxan-Derivate und diese enthaltende pharmazeutische Zusammenstellungen | |
NO924145D0 (no) | Sammensetning for faste, farmasoeytiske preparater inneholdende vitamin d3-derivat, og fremgangsmaate for fremstilling derav | |
AU3147595A (en) | Glycinamide derivatives, pharmaceutical compositions containing the same and methods utilizing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |